Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides

Neuroscience Letters

Volumn 557, Issue , 2013, Pages 27-36

  Feldman, Polina ^a   Khanna, Rajesh ^a,b,c  

^a Sophia Therapeutics LLC   (United States)

^b Department of Pharmacology and Toxicology ^*  (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti nociceptive; Calcium channels; CRMP2; Neuropathic pain; Peptide

Indexed keywords

ANALGESIC AGENT; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL CAV2.2; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL T TYPE; CNV 2197944; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; GABAPENTIN; NEUROTIN; SYNTAXIN; TAT CBD3 PEPTIDE; TUBULIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANALGESIA; ATAXIA; CENTRAL NERVOUS SYSTEM; DIABETIC NEUROPATHY; DIZZINESS; FIBROMYALGIA; HUMAN; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PHANTOM PAIN; POINT MUTATION; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PYRAMIDAL NERVE CELL; REVIEW; SENSORY NERVE CELL; SOMNOLENCE; SYNAPTOGENESIS; SYNAPTOSOME; TRIGEMINUS NEURALGIA;

ANTI-NOCICEPTIVE; BBB; BLOOD BRAIN BARRIER; CA(2+) CHANNEL BINDING DOMAIN; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNELS; CAV2.2; CBD; CELL PENETRATING PEPTIDE; CENTRAL NERVOUS SYSTEM; CGRP; CNS; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CONOTOXIN; CPP; CRMP2; CTX; DAYS IN VITRO; DIV; DORSAL ROOT GANGLION; DRG; HIV-1 TRANSACTIVATOR OF TRANSCRIPTION DOMAIN; LPC; LYSOPHOSPHOTIDYLCHOLINE; N-TYPE VOLTAGE-GATED CA(2+) CHANNEL; NEUROPATHIC PAIN; NONA-ARGININE; NRTI; NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMEGA-CONOTOXIN; PAW WITHDRAWAL THRESHOLD; PEPTIDE; PWT; R9; SEPSCS; SOPHIA THERAPEUTICS; SPONTANEOUS EXCITATORY POSTSYNAPTIC CURRENTS; ST; TAT; TIBIAL NERVE INJURY; TNI; Ω-CTX;

ANALGESICS; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; CHRONIC DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; NERVE TISSUE PROTEINS; NEURALGIA; PEPTIDES; SIGNAL TRANSDUCTION;

EID: 84890165973     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.057     Document Type: Review

References (117)

1. Abbadie C., McManus O.B., Sun S.Y., Bugianesi R.M., Dai G., Haedo R.J., Herrington J.B., Kaczorowski G.J., Smith M.M., Swensen A.M., Warren V.A., Williams B., Arneric S.P., Eduljee C., Snutch T.P., Tringham E.W., Jochnowitz N., Liang A., Euan M.D., McGowan E., Mistry S., White V.V., Hoyt S.B., London C., Lyons K.A., Bunting P.B., Volksdorf S., Duffy J.L. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J. Pharmacol. Exp. Ther. 2010, 334:545-555.
2. Achar A., Chakraborty P.P., Bisai S., Biswas A., Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol. Croatica 2012, 20:89-94.
3. Ahn S.H., Park H.W., Lee B.S., Moon H.W., Jang S.H., Sakong J., Bae J.H. Gabapentin effect on neuropathic pain compared among patients with spinal cord injury and different durations of symptoms. Spine 2003, 28:341-346. discussion 346-347.
4. Ahrens V.M., Bellmann-Sickert K., Beck-Sickinger A.G. Peptides and peptide conjugates: therapeutics on the upward path. Future Med. Chem. 2012, 4:1567-1586.
5. Albericio F., Kruger H.G. Therapeutic peptides. Future Med. Chem. 2012, 4:1527-1531.
6. Alicino I., Giglio M., Manca F., Bruno F., Puntillo F. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain 2012, 153:245-249.
7. 2+ channel intracellular linker: a structure-function analysis. J. Neurosci. 2012, 32:7602-7613.
8. Altier C., Dale C.S., Kisilevsky A.E., Chapman K., Castiglioni A.J., Matthews E.A., Evans R.M., Dickenson A.H., Lipscombe D., Vergnolle N., Zamponi G.W. Differential role of N-type calcium channel splice isoforms in pain. J. Neurosci. 2007, 27:6363-6373.
9. Alviar M.J., Hale T., Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst. Rev. 2011, CD006380.
10. Atlas D. The voltage-gated calcium channel functions as the molecular switch of synaptic transmission. Annu. Rev. Biochem. 2013, 82:607-635.
11. Ayoub M., Scheidegger D. Peptide drugs, overcoming the challenges, a growing business. Chim. Oggi 2006, 24:46-48.
12. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., LaMoreaux L., Garofalo E. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836.
13. Beal B., Moeller-Bertram T., Schilling J.M., Wallace M.S. Gabapentin for once-daily treatment of post-herpetic neuralgia: a review. Clin. Interv. Aging 2012, 7:249-255.
14. Bell T.J., Thaler C., Castiglioni A.J., Helton T.D., Lipscombe D. Cell-specific alternative splicing increases calcium channel current density in the pain pathway. Neuron 2004, 41:127-138.
15. Beuckmann C.T., Sinton C.M., Miyamoto N., Ino M., Yanagisawa M. N-type calcium channel alpha1B subunit (Cav2.2) knock-out mice display hyperactivity and vigilance state differences. J. Neurosci. 2003, 23:6793-6797.
16. Bone M., Critchley P., Buggy D.J. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg. Anesth. Pain Med. 2002, 27:481-486.
17. Borzenko A., Pajouhesh H., Morrison J.L., Tringham E., Snutch T.P., Schafer L.L. Modular, efficient synthesis of asymmetrically substituted piperazine scaffolds as potent calcium channel blockers. Bioorg. Med. Chem. Lett. 2013, 23:3257-3261.
18. Bosnjak S., Jelic S., Susnjar S., Luki V. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. J. Chemother. 2002, 14:214-219.
19. Brittain J.M. Dual regulation of voltage-and ligand-gated calcium channels by collapsin response mediator protein 2. Program in Medical Neuroscience Vol. Ph.D 2012, 224. Indiana University.
20. Brittain J.M., Chen L., Wilson S.M., Brustovetsky T., Gao X., Ashpole N.M., Molosh A.I., You H., Hudmon A., Shekhar A., White F.A., Zamponi G.W., Brustovetsky N., Chen J., Khanna R. Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J. Biol. Chem. 2011, 286:37778-37792.
21. Brittain J.M., Duarte D.B., Wilson S.M., Zhu W., Ballard C., Johnson P.L., Liu N., Xiong W., Ripsch M.S., Wang Y., Fehrenbacher J.C., Fitz S.D., Khanna M., Park C.K., Schmutzler B.S., Cheon B.M., Due M.R., Brustovetsky T., Ashpole N.M., Hudmon A., Meroueh S.O., Hingtgen C.M., Brustovetsky N., Ji R.R., Hurley J.H., Jin X., Shekhar A., Xu X.M., Oxford G.S., Vasko M.R., White F.A., Khanna R. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca(2)(+) channel complex. Nat. Med. 2011, 17:822-829.
22. Brittain J.M., Piekarz A.D., Wang Y., Kondo T., Cummins T.R., Khanna R. An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J. Biol. Chem. 2009, 284:31375-31390.
23. Brittain J.M., Wang Y., Eruvwetere O., Khanna R. Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2. FEBS Lett. 2012, 586:3813-3818.
24. Bruckdorfer T., Marder O., Albericio F. From production of peptides in milligram amounts for research to multi-tons quantities for drugs of the future. Curr. Pharm. Biotechnol. 2004, 5:29-43.
25. Bucci G., Mochida S., Stephens G.J. Inhibition of synaptic transmission and G protein modulation by synthetic CaV2.2 Ca(2)+ channel peptides. J. Physiol. 2011, 589:3085-3101.
26. 2+ channel peptides to study presynaptic function. Modulation of Presynaptic Calcium Channels 2013, 223-240. Springer Science+Business Media, Dordrecht, Germany. G.J. Stephens, S. Mochida (Eds.).
27. Buchwald P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 2010, 62:724-731.
28. W. Catterall, Z.-H. Sheng, Methods and compositions for screening for presynaptic calcium channel blockers, USA,WO 1996015149-83 1996.
29. Catterall W.A. Signaling complexes of voltage-gated sodium and calcium channels. Neurosci. Lett. 2010, 486:107-116.
30. Catterall W.A. Voltage-gated calcium channels. Cold Spring Harb. Perspect. Biol. 2011, 3:a003947.
31. Catterall W.A., Few A.P. Calcium channel regulation and presynaptic plasticity. Neuron 2008, 59:882-901.
32. Chi X.X., Schmutzler B.S., Brittain J.M., Hingtgen C.M., Nicol G.D., Khanna R. Regulation of N-type voltage-gated calcium (CaV2.2) channels and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J. Cell Sci. 2009, 23:4351-4362.
33. Chong M.S., Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs 2007, 67:569-585.
34. 2+ channels in the rat spinal cord following chronic constrictive nerve injury. Exp. Brain Res. 2002, 147:456-463.
35. Davies J.N., Zamponi G.W. Old proteins, developing roles: the regulation of calcium channels by synaptic proteins. Channels (Austin) 2008, 2:130-138.
36. Dib-Hajj S.D., Binshtok A.M., Cummins T.R., Jarvis M.F., Samad T., Zimmermann K. Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. Brain Res. Rev. 2009, 60:65-83.
37. Dib-Hajj S.D., Cummins T.R., Black J.A., Waxman S.G. Sodium channels in normal and pathological pain. Annu. Rev. Neurosci. 2010, 33:325-347.
38. Doggrell S.A. Intrathecal ziconotide for refractory pain. Expert Opin. Investig. Drugs 2004, 13:875-877.
39. Dolphin A.C. Calcium channel auxiliary alpha2delta and beta subunits: trafficking and one step beyond. Nat. Rev. Neurosci. 2012, 13:542-555.
40. Duchardt F., Fotin-Mleczek M., Schwarz H., Fischer R., Brock R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8:848-866.
41. Eroglu C., Allen N.J., Susman M.W., O'Rourke N.A., Park C.Y., Ozkan E., Chakraborty C., Mulinyawe S.B., Annis D.S., Huberman A.D., Green E.M., Lawler J., Dolmetsch R., Garcia K.C., Smith S.J., Luo Z.D., Rosenthal A., Mosher D.F., Barres B.A. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 2009, 139:380-392.
42. Feng Z.P., Doering C.J., Winkfein R.J., Beedle A.M., Spafford J.D., Zamponi G.W. Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA. J. Biol. Chem. 2003, 278:20171-20178.
43. Fuchs S.M., Raines R.T. Pathway for polyarginine entry into mammalian cells. Biochemistry 2004, 43:2438-2444.
44. Fuller J.C., Burgoyne N.J., Jackson R.M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 2009, 14:155-161.
45. Gorson K.C., Schott C., Herman R., Ropper A.H., Rand W.M. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J. Neurol. Neurosurg. Psychiatry 1999, 66:251-252.
46. Gruner W., Silva L.R. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J. Neurosci. 1994, 14:2800-2808.
47. Hatakeyama S., Wakamori M., Ino M., Miyamoto N., Takahashi E., Yoshinaga T., Sawada K., Imoto K., Tanaka I., Yoshizawa T., Nishizawa Y., Mori Y., Niidome T., Shoji S. Differential nociceptive responses in mice lacking the alpha(1B) subunit of N-type Ca(2+) channels. Neuroreport 2001, 12:2423-2427.
48. Hruby V.J. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 2002, 1:847-858.
49. Hummel G., Reineke U., Reimer U. Translating peptides into small molecules. Mol. Biosyst. 2006, 2:499-508.
50. C. Institute of Medicine Report from the Committee on Advancing Pain Research, Education, Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research 2011, The National Academies Press.
51. Ju W., Li Q., Allette Y.M., Ripsch M.S., White F.A., Khanna R. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide. J. Neurochem. 2012, 124:869-879.
52. Ju W., Li Q., Wilson S.M., Brittain J.M., Meroueh L., Khanna R. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons. Channels 2013, 3.
53. Ketz A.K. Pain management in the traumatic amputee. Crit. Care Nurs. Clin. North Am. 2008, 20:51-57. vi.
54. Khanna R., Zougman A., Stanley E.F. A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners. J. Biochem. Mol. Biol. 2007, 40:302-314.
55. 2+ channel Cav2.2 results in hyperaggressive behaviors in mice. J. Biol. Chem. 2008, 284:2738-2745.
56. Kim C., Jun K., Lee T., Kim S.S., McEnery M.W., Chin H., Kim H.L., Park J.M., Kim D.K., Jung S.J., Kim J., Shin H.S. Altered nociceptive response in mice deficient in the alpha(1B) subunit of the voltage-dependent calcium channel. Mol. Cell Neurosci. 2001, 18:235-245.
57. Kisilevsky A.E., Zamponi G.W. Presynaptic calcium channels: structure, regulators, and blockers. Handb. Exp. Pharmacol. 2008, 184:45-75.
58. Kolosov A., Aurini L., Williams E.D., Cooke I., Goodchild C.S. Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain. Pain Med. 2011, 12:923-941.
59. Kolosov A., Goodchild C.S., Cooke I. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010, 11:262-273.
60. Lax R. The future of peptide development in the pharmaceutical industry, pharmaufacturing. Int. Pept. Rev. 2010, 10-15.
61. Maggi C.A., Patacchini R., Santicioli P., Lippe I.T., Giuliani S., Geppetti P., Del Bianco E., Selleri S., Meli A. The effect of omega conotoxin GVIA, a peptide modulator of the N-type voltage sensitive calcium channels, on motor responses produced by activation of efferent and sensory nerves in mammalian smooth muscle. Naunyn-Schmiedebergs Archiv. Pharmacol. 1988, 338:107-113.
62. Maier C., Gockel H.H., Gruhn K., Krumova E.K., Edel M.A. Increased risk of suicide under intrathecal ziconotide treatment? - A warning. Pain 2011, 152:235-237.
63. Majava V., Loytynoja N., Chen W.Q., Lubec G., Kursula P. Crystal and solution structure, stability and post-translational modifications of collapsin response mediator protein 2. FEBS J. 2008, 275:4583-4596.
64. McGregor D.P. Discovering and improving novel peptide therapeutics. Curr. Opin. Pharmacol. 2008, 8:616-619.
65. Mitchell D.J., Kim D.T., Steinman L., Fathman C.G., Rothbard J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 2000, 56:318-325.
66. 2+ channels. Neuron 1996, 17:781-788.
67. Moore R.A., Wiffen P.J., Derry S., McQuay H.J. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. 2011, CD007938.
68. Morello C.M., Leckband S.G., Stoner C.P., Moorhouse D.F., Sahagian G.A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. 1999, 159:1931-1937.
69. Muller C.S., Haupt A., Bildl W., Schindler J., Knaus H.G., Meissner M., Rammner B., Striessnig J., Flockerzi V., Fakler B., Schulte U. Quantitative proteomics of the Cav2 channel nano-environments in the mammalian brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14950-14957.
70. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75:311-335.
71. Nikolajsen L., Finnerup N.B., Kramp S., Vimtrup A.S., Keller J., Jensen T.S. A randomized study of the effects of gabapentin on postamputation pain. Anesthesiology 2006, 105:1008-1015.
72. Pajouhesh H., Feng Z.P., Ding Y., Zhang L., Pajouhesh H., Morrison J.L., Belardetti F., Tringham E., Simonson E., Vanderah T.W., Porreca F., Zamponi G.W., Mitscher L.A., Snutch T.P. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett. 2010, 20:1378-1383.
73. Pajouhesh H., Feng Z.P., Zhang L., Pajouhesh H., Jiang X., Hendricson A., Dong H., Tringham E., Ding Y., Vanderah T.W., Porreca F., Belardetti F., Zamponi G.W., Mitscher L.A., Snutch T.P. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors. Bioorg. Med. Chem. Lett. 2012, 22:4153-4158.
74. Pexton T., Moeller-Bertram T., Schilling J.M., Wallace M.S. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opin. Investig. Drugs 2011, 20:1277-1284.
75. Piekarz A.D., Due M.R., Khanna M., Wang B., Ripsch M.S., Wang R., Meroueh S.O., Vasko M.R., White F.A., Khanna R. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol. Pain 2012, 8:54.
76. Prommer E. Ziconotide: a new option for refractory pain. Drugs Today (Barc) 2006, 42:369-378.
77. Prommer E.E. Ziconotide: can we use it in palliative care?. Am. J. Hosp. Palliat. care 2005, 22:369-374.
78. Quach T.T., Massicotte G., Belin M.F., Honnorat J., Glasper E.R., Devries A.C., Jakeman L.B., Baudry M., Duchemin A.M., Kolattukudy P.E. CRMP3 is required for hippocampal CA1 dendritic organization and plasticity. FASEB J. 2008, 22:401-409.
79. Rauck R.L., Wallace M.S., Burton A.W., Kapural L., North J.M. Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009, 9:327-337.
80. 2+ channels with the presynaptic proteins syntaxin and SNAP-25. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7363-7368.
81. Ripsch M.S., Ballard C.J., Khanna M., Hurley J.H., White F.A., Khanna R. A Peptide uncoupling CRMP-2 from the presynaptic ca(2+) channel complex demonstrates efficacy in animal models of migraine and aids therapy-induced neuropathy. Transl. Neurosci. 2012, 3:1-8.
82. Rowbotham M., Harden N., Stacey B., Bernstein P., Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280:1837-1842.
83. Rusy L.M., Troshynski T.J., Weisman S.J. Gabapentin in phantom limb pain management in children and young adults: report of seven cases. J. Pain Symptom Manage. 2001, 21:78-82.
84. 2+ channel. EMBO J. 2001, 20:2349-2356.
85. Schmidtko A., Lotsch J., Freynhagen R., Geisslinger G. Ziconotide for treatment of severe chronic pain. Lancet 2010, 375:1569-1577.
86. Schroeder C.I., Doering C.J., Zamponi G.W., Lewis R.J. N-type calcium channel blockers: novel therapeutics for the treatment of pain. Med. Chem. 2006, 2:535-543.
87. Scott D.A., Wright C.E., Angus J.A. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol. 2002, 451:279-286.
88. Serpell M.G. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain 2002, 99:557-566.
89. Seward E., Hammond C., Henderson G. Mu-opioid-receptor-mediated inhibition of the N-type calcium-channel current. Proc. Biol. Sci. 1991, 244:129-135.
90. Sheng Z.H., Rettig J., Cook T., Catterall W.A. Calcium-dependent interaction of N-type calcium channels with the synaptic core complex. Nature 1996, 379:451-454.
91. Sheng Z.H., Rettig J., Takahashi M., Catterall W.A. Identification of a syntaxin-binding site on N-type calcium channels. Neuron 1994, 13:1303-1313.
92. Skov M.J., Beck J.C., de Kater A.W., Shopp G.M. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int. J. Toxicol. 2007, 26:411-421.
93. Smith M.T., Cabot P.J., Ross F.B., Robertson A.D., Lewis R.J. The novel N-type calcium channel blocker AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002, 96:119-127.
94. Snutch T.P. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age. NeuroRx 2005, 2:662-670.
95. Stanley E.F. The calcium channel and the organization of the presynaptic transmitter release face. Trends Neurosci. 1997, 20:404-409.
96. Stevenson C.L. Advances in peptide pharmaceuticals. Curr. Pharm. Biotechnol. 2009, 10:122-137.
97. Su K.Y., Chien W.L., Fu W.M., Yu I.S., Huang H.P., Huang P.H., Lin S.R., Shih J.Y., Lin Y.L., Hsueh Y.P., Yang P.C., Lin S.W. Mice deficient in collapsin response mediator protein-1 exhibit impaired long-term potentiation and impaired spatial learning and memory. J. Neurosci. 2007, 27:2513-2524.
98. Swensen A.M., Herrington J., Bugianesi R.M., Dai G., Haedo R.J., Ratliff K.S., Smith M.M., Warren V.A., Arneric S.P., Eduljee C., Parker D., Snutch T.P., Hoyt S.B., London C., Duffy J.L., Kaczorowski G.J., McManus O.B. Characterization of the substituted N-triazole oxindole, TROX-1, a small molecule, state-dependent inhibitor of CaV2 calcium channels. Mol. Pharmacol. 2011.
99. Thompson J.C., Dunbar E., Laye R.R. Treatment challenges and complications with ziconotide monotherapy in established pump patients. Pain Physician 2006, 9:147-152.
100. Todorovic S.M., Jevtovic-Todorovic V. T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br. J. Pharmacol. 2011, 163:484-495.
101. Tunnemann G., Ter-Avetisyan G., Martin R.M., Stockl M., Herrmann A., Cardoso M.C. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J. Pept. Sci. 2008, 14:469-476.
102. Turner R.W., Anderson D., Zamponi G.W. Signaling complexes of voltage-gated calcium channels. Channels (Austin) 2011, 5:440-448.
103. Udall M., Harnett J., Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J. Med. Econ. 2012, 15:361-370.
104. Udall M., Mardekian J., Cabrera J. Identification of patients with painful diabetic peripheral neuropathy who have a favorable cost profile with pregabalin treatment. Pain Pract. 2013, 13:476-484.
105. Vlieghe P., Lisowski V., Martinez J., Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 2010, 15:40-56.
106. Waithe D., Ferron L., Page K.M., Chaggar K., Dolphin A.C. Beta-subunits promote the expression of Ca(V)2.2 channels by reducing their proteasomal degradation. J. Biol. Chem. 2011, 286:9598-9611.
107. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:13003-13008.
108. Westenbroek R.E., Hell J.W., Warner C., Dubel S.J., Snutch T.P., Catterall W.A. Biochemical properties and subcellular distribution of an N-type calcium channel alpha 1 subunit. Neuron 1992, 9:1099-1115.
109. Williams J.A., Day M., Heavner J.E. Ziconotide: an update and review. Expert Opin. Pharmacother. 2008, 9:1575-1583.
110. Wilson S.M., Brittain J.M., Piekarz A.D., Ballard C.J., Ripsch M.S., Cummins T.R., Hurley J.H., Khanna M., Hammes N.M., Samuels B.C., White F.A., Khanna R. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels (Austin) 2011, 5:449-456.
111. 2+ channel peptides. J. Biol. Chem. 2012, 287:35065-35077.
112. Woodley J.F. Enzymatic barriers for Gi peptide and protein delivery. Crit. Rev. Ther. Drug 1994, 11:61-95.
113. Yaksh T.L. Calcium channels as therapeutic targets in neuropathic pain. J. Pain 2006, 7:S13-S30.
114. Zamponi G.W., Feng Z.P., Zhang L., Pajouhesh H., Ding Y., Belardetti F., Pajouhesh H., Dolphin D., Mitscher L.A., Snutch T.P. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg. Med. Chem. Lett. 2009, 19:6467-6472.
115. Zamponi G.W., Lewis R.J., Todorovic S.M., Arneric S.P., Snutch T.P. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res. Rev. 2009, 60:84-89.
116. Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr. Dis. Treat. 2008, 4:1193-1201.
117. Zompra A.A., Galanis A.S., Werbitzky O., Albericio F. Manufacturing peptides as active pharmaceutical ingredients. Future Med. Chem. 2009, 1:361-377.